Monoclonal antibody therapies against SARS-CoV-2
Copyright policy )Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents.
- University of Verona Italy
- Azienda Ospedaliera Universitaria Pisana Italy
- University of Pisa Italy
HALF-LIFE, NEUTRALIZATION, NEBULIZATION, VARIANTS, MOTAVIZUMAB, MUTATIONS, INFECTION, DELIVERY, BINDING, DOMAIN, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Humans, COVID-19, Antibodies, Monoclonal, Review, Antibodies, Viral, Pandemics, Antibodies, Neutralizing
HALF-LIFE, NEUTRALIZATION, NEBULIZATION, VARIANTS, MOTAVIZUMAB, MUTATIONS, INFECTION, DELIVERY, BINDING, DOMAIN, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Humans, COVID-19, Antibodies, Monoclonal, Review, Antibodies, Viral, Pandemics, Antibodies, Neutralizing
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).147 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.1%
Citations provided by BIP!Popularity provided by BIP!